Abstract
The new hepatitis C virus (HCV) treatment regimens are safe and highly effective but costly. Because of their high price, many insurers, including Medicaid, have implemented coverage restrictions and prior-authorization requirements. To systematically evaluate state Medicaid policies for HCV treatment with sofosbuvir in the U.S., investigators searched state Medicaid websites for reimbursement criteria data from the 50 states and the District of Columbia. Data were limited to Medicaid fee-for-service beneficiaries only. …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
